X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs TORRENT PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD TORRENT PHARMA BIOCON LTD/
TORRENT PHARMA
 
P/E (TTM) x 75.8 28.4 266.6% View Chart
P/BV x 7.1 5.4 132.0% View Chart
Dividend Yield % 0.2 1.0 17.3%  

Financials

 BIOCON LTD   TORRENT PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
TORRENT PHARMA
Mar-17
BIOCON LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1621,768 65.7%   
Low Rs4831,186 40.7%   
Sales per share (Unadj.) Rs194.6346.1 56.2%  
Earnings per share (Unadj.) Rs34.455.2 62.4%  
Cash flow per share (Unadj.) Rs48.373.3 65.8%  
Dividends per share (Unadj.) Rs1.0014.00 7.1%  
Dividend yield (eoy) %0.10.9 12.8%  
Book value per share (Unadj.) Rs241.9257.1 94.1%  
Shares outstanding (eoy) m200.00169.22 118.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.3 99.1%   
Avg P/E ratio x23.926.8 89.3%  
P/CF ratio (eoy) x17.020.1 84.6%  
Price / Book Value ratio x3.45.7 59.2%  
Dividend payout %2.925.4 11.5%   
Avg Mkt Cap Rs m164,440249,887 65.8%   
No. of employees `0009.211.8 78.4%   
Total wages/salary Rs m7,4709,934 75.2%   
Avg. sales/employee Rs Th4,213.94,971.5 84.8%   
Avg. wages/employee Rs Th809.0843.2 95.9%   
Avg. net profit/employee Rs Th745.2792.4 94.0%   
INCOME DATA
Net Sales Rs m38,91158,569 66.4%  
Other income Rs m1,5712,233 70.4%   
Total revenues Rs m40,48260,802 66.6%   
Gross profit Rs m9,79513,773 71.1%  
Depreciation Rs m2,7723,069 90.3%   
Interest Rs m2602,056 12.6%   
Profit before tax Rs m8,33410,881 76.6%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6161,545 104.6%   
Profit after tax Rs m6,8819,336 73.7%  
Gross profit margin %25.223.5 107.0%  
Effective tax rate %19.414.2 136.6%   
Net profit margin %17.715.9 110.9%  
BALANCE SHEET DATA
Current assets Rs m40,47753,841 75.2%   
Current liabilities Rs m16,78331,612 53.1%   
Net working cap to sales %60.938.0 160.4%  
Current ratio x2.41.7 141.6%  
Inventory Days Days6097 61.3%  
Debtors Days Days8384 98.9%  
Net fixed assets Rs m45,07342,079 107.1%   
Share capital Rs m1,000846 118.2%   
"Free" reserves Rs m47,37742,655 111.1%   
Net worth Rs m48,37743,501 111.2%   
Long term debt Rs m21,08222,408 94.1%   
Total assets Rs m93,942101,250 92.8%  
Interest coverage x33.16.3 525.2%   
Debt to equity ratio x0.40.5 84.6%  
Sales to assets ratio x0.40.6 71.6%   
Return on assets %7.611.3 67.6%  
Return on equity %14.221.5 66.3%  
Return on capital %12.619.6 64.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98820,066 64.7%   
Fx outflow Rs m7,8995,304 148.9%   
Net fx Rs m5,08914,762 34.5%   
CASH FLOW
From Operations Rs m6,40010,127 63.2%  
From Investments Rs m-4,985-7,869 63.3%  
From Financial Activity Rs m-1,775-1,918 92.5%  
Net Cashflow Rs m-473212 -223.6%  

Share Holding

Indian Promoters % 40.4 71.5 56.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.0 119.7%  
FIIs % 10.7 12.6 84.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.8 226.1%  
Shareholders   109,995 26,511 414.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 20, 2018 11:57 AM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS